Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Debt: 2009-2024

Historic Total Debt for Cumberland Pharmaceuticals (CPIX) over the last 14 years, with Dec 2024 value amounting to $15.3 million.

  • Cumberland Pharmaceuticals' Total Debt fell 67.43% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year decrease of 49.23%. This contributed to the annual value of $15.3 million for FY2024, which is 19.49% up from last year.
  • As of FY2024, Cumberland Pharmaceuticals' Total Debt stood at $15.3 million, which was up 19.49% from $12.8 million recorded in FY2023.
  • In the past 5 years, Cumberland Pharmaceuticals' Total Debt ranged from a high of $16.2 million in FY2022 and a low of $12.8 million during FY2023.
  • Its 3-year average for Total Debt is $14.8 million, with a median of $15.3 million in 2024.
  • In the last 5 years, Cumberland Pharmaceuticals' Total Debt declined by 21.09% in 2023 and then rose by 19.49% in 2024.
  • Over the past 5 years, Cumberland Pharmaceuticals' Total Debt (Yearly) stood at $15.0 million in 2020, then remained steady at $15.0 million in 2021, then increased by 8.00% to $16.2 million in 2022, then dropped by 21.09% to $12.8 million in 2023, then climbed by 19.49% to $15.3 million in 2024.